A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Conclusions AMG 900 40 mg/day with G-CSF had manageable toxicity and demonstrated single-agent activity in patients with heavily pretreated, chemotherapy-resistant ovarian cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Ovarian Cancer | Ovaries | Prostate Cancer | Study | Thrombocytopenia | Toxicology